// App-Quantinova.ai

181 : Efficacy and safety of ixekizumab at week 52 in biologic naïve patients with active psoriatic arthritis (SPIRIT-P1)

Researchers

Presenter

  • Eric Lespessailles

Principal Investigators

  • Bruce Kirkham

  • Antonio Fernandez Nebro

  • Ricardo Blanco

  • Christoph Strehblow

  • Jose Inciarte-Mundo

  • Vibeke Porsdal

  • Miriam Garcia

  • Monika Kurzawa

  • Christophe Sapin

  • Piet Geusens

  • Philippe Goupille

  • Hasan Tahir

Medical Centers

  • Rheumatology, Hospital La Source, University of Orleans, Orleans, FRANCE

  • Rheumatology, Guy’s & St Thomas’ NHS Foundation, Trust and King's College, London, UNITED KINGDOM

  • Rheumatology, Hospital Regional Universitario de Málaga, Universidad de Málaga, Malaga, SPAIN

  • Rheumatology, University Hospital Valdecilla, Universidad de Cantabria, Santander, SPAIN

  • Lilly International, Eli Lilly and Company, Indianapolis, IN

  • Biomedical Research Centre, University of Hasselt, Diepenbeek, BELGIUM

  • Service d’hématologie, CHU Tours, Tours, FRANCE

  • Rheumatology, University Hospital Whipps Cross Road, London, UNITED KINGDOM

Locations

  • France

  • United Kingdom

  • Spain

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01695239

Sponsors

  • Eli Lilly and Company

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved